Antineoplastic - Immunotherapy, T-cell Engager

Antineoplastic T-cell engager immunotherapies are engineered multispecific biologic agents designed to redirect endogenous cytotoxic T cells to destroy malignant cells

Antineoplastic T-cell engager immunotherapies are engineered multispecific biologic agents designed to redirect endogenous cytotoxic T cells to destroy malignant cells Their primary mechanism of action involves simultaneously binding to the CD3 subunit of the T-cell receptor complex and a specific tumor-associated antigen, forming an immunological synapse that triggers targeted, MHC-independent cytolytic killing

Their primary mechanism of action involves simultaneously binding to the CD3 subunit of the T-cell receptor complex and a specific tumor-associated antigen, forming an immunological synapse that triggers targeted, MHC-independent cytolytic killing

These therapies are widely utilized in the treatment of hematologic malignancies, such as acute lymphoblastic leukemia, multiple myeloma, and non-Hodgkin lymphomas, as well as selected solid tumors including small cell lung cancer and uveal melanoma

These therapies are widely utilized in the treatment of hematologic malignancies, such as acute lymphoblastic leukemia, multiple myeloma, and non-Hodgkin lymphomas, as well as selected solid tumors including small cell lung cancer and uveal melanoma

These therapies are widely utilized in the treatment of hematologic malignancies, such as acute lymphoblastic leukemia, multiple myeloma, and non-Hodgkin lymphomas, as well as selected solid tumors including small cell lung cancer and uveal melanoma

These therapies are widely utilized in the treatment of hematologic malignancies, such as acute lymphoblastic leukemia, multiple myeloma, and non-Hodgkin lymphomas, as well as selected solid tumors including small cell lung cancer and uveal melanoma